Her scientific interests lie mostly in Pathology, Dermatology, Lymphoma, Immunology and Internal medicine. Martine Bagot has included themes like Peripheral T-cell lymphoma and Gene rearrangement in her Pathology study. The various areas that Martine Bagot examines in her Dermatology study include Vasculitis, Disease, Pseudolymphoma and Arthritis.
Her study on Cutaneous lymphoma and B symptoms is often connected to Primary Cutaneous Diffuse Large B-Cell Lymphoma as part of broader study in Lymphoma. Her work in Immunology addresses issues such as Cytotoxic T cell, which are connected to fields such as CD8. Her Internal medicine research is multidisciplinary, relying on both Gastroenterology and Oncology.
The scientist’s investigation covers issues in Dermatology, Pathology, Lymphoma, Internal medicine and Immunology. Her study looks at the intersection of Dermatology and topics like Mycosis fungoides with Stage. Her research combines Peripheral T-cell lymphoma and Pathology.
Lymphoma is closely attributed to Cancer in her work. Martine Bagot interconnects Gastroenterology, Surgery and Oncology in the investigation of issues within Internal medicine. As part of her studies on Immunology, she frequently links adjacent subjects like Cytotoxic T cell.
Her main research concerns Dermatology, Internal medicine, Mycosis fungoides, Cutaneous T-cell lymphoma and Oncology. Her Dermatology study integrates concerns from other disciplines, such as Disease, Retrospective cohort study, MEDLINE and Lymphoma. Her biological study spans a wide range of topics, including Cancer and Flow cytometry.
The study incorporates disciplines such as Gastroenterology and KIR3DL2 in addition to Internal medicine. Specifically, her work in Mycosis fungoides is concerned with the study of Cutaneous lymphoma. Her Cutaneous T-cell lymphoma research is multidisciplinary, incorporating elements of Cancer research and Brentuximab vedotin.
Martine Bagot mainly investigates Dermatology, Internal medicine, Atopic dermatitis, Mycosis fungoides and Coronavirus disease 2019. Martine Bagot has researched Dermatology in several fields, including MEDLINE, Infliximab, Retrospective cohort study, Heterogeneous group and Necrobiosis lipoidica. Her work in the fields of Internal medicine, such as Lymphoma, overlaps with other areas such as In patient.
Her Lymphoma study incorporates themes from KIR3DL2, Clinical trial, Flow cytometry and Prospective cohort study. Scleroderma, Epidermolysis bullosa acquisita and Pemphigus is closely connected to Disease in her research, which is encompassed under the umbrella topic of Atopic dermatitis. When carried out as part of a general Mycosis fungoides research project, her work on Cutaneous lymphoma is frequently linked to work in Systemic therapy, therefore connecting diverse disciplines of study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS).
Hélène Bocquet;Martine Bagot;Jean Claude Roujeau.
Seminars in Cutaneous Medicine and Surgery (1996)
Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
Elise A. Olsen;Sean Whittaker;Youn H. Kim;Madeleine Duvic.
Journal of Clinical Oncology (2011)
European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas.
Nancy J. Senff;Evert M. Noordijk;Youn H. Kim;Martine Bagot.
Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells
Amal Nassif;Armand Bensussan;Laurence Boumsell;Aurelien Deniaud.
The Journal of Allergy and Clinical Immunology (2004)
EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma
Werner Kempf;Katrin Pfaltz;Maarten H. Vermeer;Antonio Cozzio.
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H Miles Prince;H Miles Prince;Youn H Kim;Steven M Horwitz;Reinhard Dummer.
The Lancet (2017)
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017
Franz Trautinger;Johanna Eder;Chalid Assaf;Martine Bagot.
European Journal of Cancer (2017)
Drug Specific Cytotoxic T-Cells in the Skin Lesions of a Patient with Toxic Epidermal Necrolysis
Amal Nassif;Armand Bensussan;Guillaume Dorothée;Fathia Mami-Chouaib.
Journal of Investigative Dermatology (2002)
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review.
Tony Petrella;Martine Bagot;Rein Willemze;Marie Beylot-Barry.
American Journal of Clinical Pathology (2005)
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model
Julia J. Scarisbrick;H. Miles Prince;Maarten H. Vermeer;Pietro Quaglino.
Journal of Clinical Oncology (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: